RLYB (Rallybio Corporation Common Stock) Stock Analysis - Analyst Ratings

Rallybio Corporation Common Stock (RLYB) is a publicly traded Healthcare sector company. As of May 21, 2026, RLYB trades at $14.43 with a market cap of $74.70M and a P/E ratio of -5.06. RLYB moved +2.18% today. Year to date, RLYB is +168.41%; over the trailing twelve months it is +427.04%. Its 52-week range spans $1.76 to $15.31. Rallies surfaces RLYB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate RLYB?

The average price target is $0.00.

RLYB Key Metrics

Key financial metrics for RLYB
MetricValue
Price$14.43
Market Cap$74.70M
P/E Ratio-5.06
EPS$-2.84
Dividend Yield0.00%
52-Week High$15.31
52-Week Low$1.76
Volume86
Avg Volume0
Revenue (TTM)$858.00K
Net Income$-7.82M
Gross Margin0.00%

RLYB Analyst Consensus

RLYB analyst coverage data. Average price target: $0.00.

Latest RLYB News

Recent RLYB Insider Trades

  • ADAR1 Capital Management, LLC bought 10.00K (~$139.82K) on May 19, 2026.
  • ADAR1 Capital Management, LLC bought 200 (~$2.76K) on May 19, 2026.
  • ADAR1 Capital Management, LLC bought 6.01K (~$83.98K) on May 18, 2026.

Common questions about RLYB

What do analysts rate RLYB?
The average price target is $0.00.
Does Rallies show RLYB price targets?
Yes. Rallies tracks RLYB analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is RLYB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RLYB. It does not provide personalized investment advice.
RLYB

RLYB